112例造血干细胞移植总结报告

目的 :评价造血干细胞移植 (HSCT)治疗血液病的临床疗效及并发症。方法 :112例血液病患者行HSCT ,其中自体HSCT(auto -HSCT) 52例 ,混合HSCT(mixed -HSCT) 3 3例 ,异基因HSCT(allo -HSCT) 2 7例。结果 :随访平均 64个月 (2月～ 2 0年 ) ,62例 (55.4% )无病存活 ,其中 :auto -HSCT2 7/ 52例 (51.9% ) ,mixed -HSCT19/ 3 3例 (57.6% ) ,allo -HSCT16/ 2 7例 (59.3 % )。 51例(45.5% )死亡 ,其中 :auto -HSCT :18/ 52例 (3 4 .6% )复发死亡 ;7/ 52例 (13 .5% )移植相关死亡 ;mixed -HSCT :19/ 3 3例 (2 4.2 % )复发死亡 ;6/ 3 3例 (18.2 % )移植相关死亡 ;allo -HSCT :3 / 2 7例 (11.1% )复发死亡 ;2 / 2 7例 (7.4% )GVHD引起肝功衰竭死亡 ;6/2 7例 (2 2 .1% )移植相关死亡。结论 :HSCT治疗疗效确切 ,可提高长期无病生存

Retrospective analysis of 112 cases of hematopoietic stem cell transplantation

Objective:To evaluate the clinical effic acy and complication of hematopoietic stem cell transplantation(HSCT) in 112 patients with hematopoietic disease. Methods:112 pa tients with hematopoietic disease received HSCT, including 52 cases of auto-HSCT,33 cases of mixed-HSCT, 27 cases of allo-HSCT.Resul ts:The median follow-up duration was 64(2-240) months,62 cases (55.4%) of all were alive in a disease-free situation, including:auto-HSC T:27/52 (51.9%), mixed-HSCT 19/33(57.6%), allo-HSCT 16/27 (59.3%).51 patients died,including:auto-HSCT:18/55(34.6%) patients died from relapse and 7/25(13.5%)from transplantation related mortality(TRM);mixed-HSCT:8/33(24.2%) patients died from TRM and 6/33(18.2%)from relapse;allo-HSCT:3/27(11.1%)patients died from relapse,6/27(22.1%)from TRM,and 2/27(7.4%)from liv er aGVHD.Conclusion:HSCT had a good efficacy in the treatment of hematopoietic disease, especially in malignant hema topoietic disease and can enhance the disease-free survival.